Discovery of efficient anti-cancer drug combinations is a major challenge, since experimental testing of all possible combinations is clearly impossible. Recent efforts to computationally predict drug combination responses retain this experimental search space, as model definitions typically rely on extensive drug perturbation data. We developed a dynamical model representing a cell fate decision network in the AGS gastric cancer cell line, relying on background knowledge extracted from literature and databases. We defined a set of logical equations recapitulating AGS data observed in cells in their baseline proliferative state. Using the modeling software GINsim, model reduction and simulation compression techniques were applied to cope with the vast state space of large logical models and enable simulations of pairwise applications of specific signaling inhibitory chemical substances. Our simulations predicted synergistic growth inhibitory action of five combinations from a total of 21 possible pairs. Four of the predicted synergies were confirmed in AGS cell growth real-time assays, including known effects of combined MEK-AKT or MEK-PI3K inhibitions, along with novel synergistic effects of combined TAK1-AKT or TAK1-PI3K inhibitions. Our strategy reduces the dependence on a priori drug perturbation experimentation for well-characterized signaling networks, by demonstrating that a model predictive of combinatorial drug effects can be inferred from background knowledge on unperturbed and proliferating cancer cells. Our modeling approach can thus contribute to preclinical discovery of efficient anticancer drug combinations, and thereby to development of strategies to tailor treatment to individual cancer patients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567168PMC
http://dx.doi.org/10.1371/journal.pcbi.1004426DOI Listing

Publication Analysis

Top Keywords

gastric cancer
8
cancer cells
8
discovery efficient
8
drug combinations
8
drug perturbation
8
background knowledge
8
effects combined
8
drug
6
discovery drug
4
drug synergies
4

Similar Publications

Background: is a gram-negative pathogen. The infection caused by this pathogen may result in gastritis and can increase the risk of gastric cancer. This study investigated the relationship between infection as the main risk factor for gastritis and changes in serum inflammatory cytokine levels.

View Article and Find Full Text PDF

Granular cell tumors (GCTs) of the gastrointestinal tract are rare neoplasms often detected incidentally as subepithelial lesions during endoscopic examination. The occurrence of GCTs in the gastric cavity is even rarer. So far, there have been only four reports of multifocal gastric GCTs.

View Article and Find Full Text PDF

Introduction: Gastric cancer (GC) is among the deadliest malignancies globally, characterized by hypoxia-driven pathways that promote cancer progression, including stemness mechanisms facilitating invasion and metastasis. This study aimed to develop a prognostic decision tree using genes implicated in hypoxia and stemness pathways to predict outcomes in GC patients.

Materials And Methods: GC RNA-seq data from The Cancer Genome Atlas (TCGA) were analyzed to compute hypoxia and stemness scores using Gene Set Variation Analysis (GSVA) and the mRNA expression-based stemness index (mRNAsi).

View Article and Find Full Text PDF

Introduction: The relationship between physical activity (PA) and nutritional status on the prognosis of cancer survivors remains underexplored. We aimed to investigate the combined effects of PA and Geriatric Nutritional Risk Index (GNRI) on prognostic assessment of survival outcomes in US cancer survivors.

Methods: 2,619 subjects were screened from the National Health and Nutrition Examination Survey (NHANES) database from 1999 to 2018.

View Article and Find Full Text PDF

High-intensity focused ultrasound thermal ablation (HIFU) is a novel non-invasive technique in the treatment of liver metastases (LIM) that allows focal destruction and is not affected by dose limits. This retrospective study aimed to explore the efficacy of HIFU in improving survival and the safety of the method in newly diagnosed patients with cancer with LIM who received first-line immune checkpoint inhibitor (ICI) therapy. Between January 2018 and December 2023, data from 438 newly diagnosed patients with cancer and LIM who were treated at Mianyang Central Hospital (Mianyang, China) were reviewed.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!